Trials / Completed
CompletedNCT01485406
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 23 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study entry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumococcal vaccine GSK2830930A | 1 dose administered intramuscularly |
| BIOLOGICAL | Synflorix™ | 1 dose administered intramuscularly |
Timeline
- Start date
- 2011-12-12
- Primary completion
- 2012-03-15
- Completion
- 2012-03-15
- First posted
- 2011-12-05
- Last updated
- 2021-02-10
Locations
4 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01485406. Inclusion in this directory is not an endorsement.